instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ventricular fibrillation'. | Spontaneous Termination of Ventricular Fibrillation: Is Organization Required?
Ventricular fibrillation is a life-threatening arrhythmia that can result in sudden cardiac death and almost always requires emergency electrical defibrillation. This paper presents a unique case of a 74-year-old woman with spontaneous termi... | AMIODARONE, APIXABAN, PANTOPRAZOLE, ROSUVASTATIN | DrugsGivenReaction | CC BY-NC-ND | 34317692 | 19,609,278 | 2021-07-21 |
What was the administration route of drug 'AMIODARONE'? | Spontaneous Termination of Ventricular Fibrillation: Is Organization Required?
Ventricular fibrillation is a life-threatening arrhythmia that can result in sudden cardiac death and almost always requires emergency electrical defibrillation. This paper presents a unique case of a 74-year-old woman with spontaneous termi... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34317692 | 19,575,011 | 2021-07-21 |
What was the administration route of drug 'APIXABAN'? | Spontaneous Termination of Ventricular Fibrillation: Is Organization Required?
Ventricular fibrillation is a life-threatening arrhythmia that can result in sudden cardiac death and almost always requires emergency electrical defibrillation. This paper presents a unique case of a 74-year-old woman with spontaneous termi... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34317692 | 19,609,278 | 2021-07-21 |
What was the administration route of drug 'PANTOPRAZOLE'? | Spontaneous Termination of Ventricular Fibrillation: Is Organization Required?
Ventricular fibrillation is a life-threatening arrhythmia that can result in sudden cardiac death and almost always requires emergency electrical defibrillation. This paper presents a unique case of a 74-year-old woman with spontaneous termi... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34317692 | 19,609,278 | 2021-07-21 |
What was the administration route of drug 'ROSUVASTATIN'? | Spontaneous Termination of Ventricular Fibrillation: Is Organization Required?
Ventricular fibrillation is a life-threatening arrhythmia that can result in sudden cardiac death and almost always requires emergency electrical defibrillation. This paper presents a unique case of a 74-year-old woman with spontaneous termi... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34317692 | 19,609,278 | 2021-07-21 |
What was the outcome of reaction 'Left ventricular end-diastolic pressure increased'? | Spontaneous Termination of Ventricular Fibrillation: Is Organization Required?
Ventricular fibrillation is a life-threatening arrhythmia that can result in sudden cardiac death and almost always requires emergency electrical defibrillation. This paper presents a unique case of a 74-year-old woman with spontaneous termi... | Recovered | ReactionOutcome | CC BY-NC-ND | 34317692 | 19,575,011 | 2021-07-21 |
What was the outcome of reaction 'Syncope'? | Spontaneous Termination of Ventricular Fibrillation: Is Organization Required?
Ventricular fibrillation is a life-threatening arrhythmia that can result in sudden cardiac death and almost always requires emergency electrical defibrillation. This paper presents a unique case of a 74-year-old woman with spontaneous termi... | Recovered | ReactionOutcome | CC BY-NC-ND | 34317692 | 19,609,278 | 2021-07-21 |
What was the outcome of reaction 'Ventricular fibrillation'? | Spontaneous Termination of Ventricular Fibrillation: Is Organization Required?
Ventricular fibrillation is a life-threatening arrhythmia that can result in sudden cardiac death and almost always requires emergency electrical defibrillation. This paper presents a unique case of a 74-year-old woman with spontaneous termi... | Recovered | ReactionOutcome | CC BY-NC-ND | 34317692 | 19,609,278 | 2021-07-21 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant melanoma'. | The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.
In this narrative review, we analyze pre-registration and post-marketing data concerning hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of relapsing-remitting multiple sc... | FINGOLIMOD | DrugsGivenReaction | CC BY-NC | 34319570 | 19,693,753 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Non-Hodgkin^s lymphoma'. | The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.
In this narrative review, we analyze pre-registration and post-marketing data concerning hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of relapsing-remitting multiple sc... | FINGOLIMOD | DrugsGivenReaction | CC BY-NC | 34319570 | 19,693,753 | 2021-08 |
What was the administration route of drug 'FINGOLIMOD'? | The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.
In this narrative review, we analyze pre-registration and post-marketing data concerning hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of relapsing-remitting multiple sc... | Oral | DrugAdministrationRoute | CC BY-NC | 34319570 | 19,693,753 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Large intestine perforation'. | Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (... | LENALIDOMIDE, TEMSIROLIMUS | DrugsGivenReaction | CC BY-NC | 34320785 | 19,722,720 | 2021-07-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myocardial infarction'. | Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (... | LENALIDOMIDE, TEMSIROLIMUS | DrugsGivenReaction | CC BY-NC | 34320785 | 19,722,721 | 2021-07-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonitis'. | Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (... | LENALIDOMIDE, TEMSIROLIMUS | DrugsGivenReaction | CC BY-NC | 34320785 | 19,685,770 | 2021-07-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (... | LENALIDOMIDE, TEMSIROLIMUS | DrugsGivenReaction | CC BY-NC | 34320785 | 19,722,718 | 2021-07-29 |
What was the administration route of drug 'LENALIDOMIDE'? | Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (... | Oral | DrugAdministrationRoute | CC BY-NC | 34320785 | 19,722,718 | 2021-07-29 |
What was the administration route of drug 'TEMSIROLIMUS'? | Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34320785 | 19,722,718 | 2021-07-29 |
What was the outcome of reaction 'Large intestine perforation'? | Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (... | Fatal | ReactionOutcome | CC BY-NC | 34320785 | 19,722,720 | 2021-07-29 |
What was the outcome of reaction 'Myocardial infarction'? | Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (... | Fatal | ReactionOutcome | CC BY-NC | 34320785 | 19,722,721 | 2021-07-29 |
What was the outcome of reaction 'Sepsis'? | Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (... | Fatal | ReactionOutcome | CC BY-NC | 34320785 | 19,722,718 | 2021-07-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute respiratory failure'. | Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics.
BACKGROUND
Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The... | METHOTREXATE | DrugsGivenReaction | CC BY | 34320981 | 19,694,388 | 2021-07-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulmonary toxicity'. | Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics.
BACKGROUND
Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The... | METHOTREXATE SODIUM | DrugsGivenReaction | CC BY | 34320981 | 19,755,768 | 2021-07-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Traumatic lung injury'. | Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics.
BACKGROUND
Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The... | METHOTREXATE | DrugsGivenReaction | CC BY | 34320981 | 19,694,388 | 2021-07-28 |
What was the outcome of reaction 'Acute respiratory failure'? | Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics.
BACKGROUND
Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The... | Recovered | ReactionOutcome | CC BY | 34320981 | 19,694,388 | 2021-07-28 |
What was the outcome of reaction 'Pulmonary toxicity'? | Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics.
BACKGROUND
Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The... | Recovered | ReactionOutcome | CC BY | 34320981 | 19,755,768 | 2021-07-28 |
What was the outcome of reaction 'Traumatic lung injury'? | Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics.
BACKGROUND
Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The... | Recovered | ReactionOutcome | CC BY | 34320981 | 19,694,388 | 2021-07-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated gastritis'. | Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presen... | AMLODIPINE BESYLATE, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, RAMIPRIL | DrugsGivenReaction | CC BY-NC-ND | 34321417 | 19,765,907 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated myocarditis'. | Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presen... | AMLODIPINE BESYLATE, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, RAMIPRIL | DrugsGivenReaction | CC BY-NC-ND | 34321417 | 19,765,907 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated oesophagitis'. | Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presen... | AMLODIPINE BESYLATE, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, RAMIPRIL | DrugsGivenReaction | CC BY-NC-ND | 34321417 | 19,765,907 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presen... | AMLODIPINE BESYLATE, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, RAMIPRIL | DrugsGivenReaction | CC BY-NC-ND | 34321417 | 19,765,907 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Toxic epidermal necrolysis'. | Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presen... | AMLODIPINE BESYLATE, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, RAMIPRIL | DrugsGivenReaction | CC BY-NC-ND | 34321417 | 19,765,907 | 2021-07-30 |
What was the outcome of reaction 'Immune-mediated gastritis'? | Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presen... | Recovered | ReactionOutcome | CC BY-NC-ND | 34321417 | 19,765,907 | 2021-07-30 |
What was the outcome of reaction 'Immune-mediated myocarditis'? | Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presen... | Recovered | ReactionOutcome | CC BY-NC-ND | 34321417 | 19,765,907 | 2021-07-30 |
What was the outcome of reaction 'Immune-mediated oesophagitis'? | Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presen... | Recovered | ReactionOutcome | CC BY-NC-ND | 34321417 | 19,765,907 | 2021-07-30 |
What was the outcome of reaction 'Toxic epidermal necrolysis'? | Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presen... | Recovered | ReactionOutcome | CC BY-NC-ND | 34321417 | 19,765,907 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug dependence'. | Quetiapine, Misuse and Dependency: A Case-Series of Questions to a Norwegian Network of Drug Information Centers.
The second-generation antipsychotic quetiapine has been associated with misuse and dependency. We aimed to review questions to the Norwegian network of drug information centers concerning this potential dru... | QUETIAPINE | DrugsGivenReaction | CC BY-NC | 34321931 | 20,227,517 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Quetiapine, Misuse and Dependency: A Case-Series of Questions to a Norwegian Network of Drug Information Centers.
The second-generation antipsychotic quetiapine has been associated with misuse and dependency. We aimed to review questions to the Norwegian network of drug information centers concerning this potential dru... | QUETIAPINE | DrugsGivenReaction | CC BY-NC | 34321931 | 20,227,517 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma.
Background: Active vitreous seeds in eyes with retinoblastoma (Rb) adversely affects the treatment outcome. This study aimed to investigate the safety and efficacy of intravitreal melphalan chemotherapy (IViC) as a t... | CARBOPLATIN, ETOPOSIDE, MELPHALAN, VINCRISTINE | DrugsGivenReaction | CC BY | 34322023 | 20,408,990 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use issue'. | Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma.
Background: Active vitreous seeds in eyes with retinoblastoma (Rb) adversely affects the treatment outcome. This study aimed to investigate the safety and efficacy of intravitreal melphalan chemotherapy (IViC) as a t... | CARBOPLATIN, ETOPOSIDE, MELPHALAN, VINCRISTINE | DrugsGivenReaction | CC BY | 34322023 | 20,408,990 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma.
Background: Active vitreous seeds in eyes with retinoblastoma (Rb) adversely affects the treatment outcome. This study aimed to investigate the safety and efficacy of intravitreal melphalan chemotherapy (IViC) as a t... | CARBOPLATIN, ETOPOSIDE, MELPHALAN, VINCRISTINE | DrugsGivenReaction | CC BY | 34322023 | 20,408,990 | 2021 |
What was the administration route of drug 'CARBOPLATIN'? | Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma.
Background: Active vitreous seeds in eyes with retinoblastoma (Rb) adversely affects the treatment outcome. This study aimed to investigate the safety and efficacy of intravitreal melphalan chemotherapy (IViC) as a t... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34322023 | 20,408,990 | 2021 |
What was the administration route of drug 'MELPHALAN'? | Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma.
Background: Active vitreous seeds in eyes with retinoblastoma (Rb) adversely affects the treatment outcome. This study aimed to investigate the safety and efficacy of intravitreal melphalan chemotherapy (IViC) as a t... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34322023 | 20,408,990 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant... | BORTEZOMIB, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, LENALIDOMIDE, PREDNISONE, VINCRISTINE | DrugsGivenReaction | CC BY | 34322131 | 19,688,453 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant... | BORTEZOMIB, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, LENALIDOMIDE, PREDNISONE, VINCRISTINE | DrugsGivenReaction | CC BY | 34322131 | 19,688,453 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant... | BORTEZOMIB, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, LENALIDOMIDE, PREDNISONE, VINCRISTINE | DrugsGivenReaction | CC BY | 34322131 | 19,688,453 | 2021 |
What was the administration route of drug 'LENALIDOMIDE'? | Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant... | Oral | DrugAdministrationRoute | CC BY | 34322131 | 19,688,453 | 2021 |
What was the dosage of drug 'BORTEZOMIB'? | Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant... | 1.3 MILLIGRAM/SQ. METER | DrugDosageText | CC BY | 34322131 | 19,688,453 | 2021 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant... | 400 MILLIGRAM/SQ. METER | DrugDosageText | CC BY | 34322131 | 19,688,453 | 2021 |
What was the dosage of drug 'DOXORUBICIN HYDROCHLORIDE'? | Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant... | 20 MILLIGRAM | DrugDosageText | CC BY | 34322131 | 19,688,453 | 2021 |
What was the dosage of drug 'LENALIDOMIDE'? | Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant... | 25 MILLIGRAM | DrugDosageText | CC BY | 34322131 | 19,688,453 | 2021 |
What was the dosage of drug 'PREDNISONE'? | Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant... | 40 MILLIGRAM/SQ. METER | DrugDosageText | CC BY | 34322131 | 19,688,453 | 2021 |
What was the dosage of drug 'VINCRISTINE'? | Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant... | 1 MILLIGRAM/SQ. METER | DrugDosageText | CC BY | 34322131 | 19,688,453 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Sequential development of ANCA-associated vasculitis and anti-GBM disease: A report of two cases.
In case of AAV with kidney involvement, physicians should explore anti-GBM antibodies and be aware of the possible sequential development of AAV, especially with MPO-ANCA, and anti-GBM glomerulonephritis. This sequential d... | CYCLOPHOSPHAMIDE, RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 34322270 | 20,178,685 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'End stage renal disease'. | Sequential development of ANCA-associated vasculitis and anti-GBM disease: A report of two cases.
In case of AAV with kidney involvement, physicians should explore anti-GBM antibodies and be aware of the possible sequential development of AAV, especially with MPO-ANCA, and anti-GBM glomerulonephritis. This sequential d... | CYCLOPHOSPHAMIDE, RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 34322270 | 20,178,685 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Sequential development of ANCA-associated vasculitis and anti-GBM disease: A report of two cases.
In case of AAV with kidney involvement, physicians should explore anti-GBM antibodies and be aware of the possible sequential development of AAV, especially with MPO-ANCA, and anti-GBM glomerulonephritis. This sequential d... | CYCLOPHOSPHAMIDE, RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 34322270 | 20,178,685 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anti-neutrophil cytoplasmic antibody positive vasculitis'. | Looks can be Deceiving: A Challenging Case of Anti-Neutrophil Cytoplasmic Autoantibody Associated Vasculitis.
[Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis] (AAV) is an autoimmune disease characterized by systemic vascular inflammation. We present a case of a 76-year-old man who presented with ... | HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, LOSARTAN | DrugsGivenReaction | CC BY | 34322348 | 20,122,775 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Glomerulonephritis rapidly progressive'. | Looks can be Deceiving: A Challenging Case of Anti-Neutrophil Cytoplasmic Autoantibody Associated Vasculitis.
[Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis] (AAV) is an autoimmune disease characterized by systemic vascular inflammation. We present a case of a 76-year-old man who presented with ... | HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, LOSARTAN | DrugsGivenReaction | CC BY | 34322348 | 20,122,775 | 2021-06 |
What was the dosage of drug 'HYDRALAZINE HYDROCHLORIDE'? | Looks can be Deceiving: A Challenging Case of Anti-Neutrophil Cytoplasmic Autoantibody Associated Vasculitis.
[Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis] (AAV) is an autoimmune disease characterized by systemic vascular inflammation. We present a case of a 76-year-old man who presented with ... | UNK, HYDRALAZINE WAS RESUMED | DrugDosageText | CC BY | 34322348 | 20,122,775 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatorenal syndrome'. | Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure.
ACLF is characterized by acute deterioration of liver function in patients with chronic liver disease. HBV is one of the most important causes of both acute insult and underlying chronic liver disease in ACLF. Reactiva... | TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY-NC-SA | 34322442 | 19,661,606 | 2021-06 |
What was the administration route of drug 'TENOFOVIR DISOPROXIL FUMARATE'? | Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure.
ACLF is characterized by acute deterioration of liver function in patients with chronic liver disease. HBV is one of the most important causes of both acute insult and underlying chronic liver disease in ACLF. Reactiva... | Oral | DrugAdministrationRoute | CC BY-NC-SA | 34322442 | 19,661,606 | 2021-06 |
What was the outcome of reaction 'Hepatorenal syndrome'? | Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure.
ACLF is characterized by acute deterioration of liver function in patients with chronic liver disease. HBV is one of the most important causes of both acute insult and underlying chronic liver disease in ACLF. Reactiva... | Fatal | ReactionOutcome | CC BY-NC-SA | 34322442 | 19,661,606 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cholecystitis acute'. | Epstein-Barr Virus (EBV) acute acalculous cholecystitis in an immunocompromised adult patient: a case report and a literature review of a neglected clinical presentation.
Primary Epstein-Barr virus (EBV) infection may present with self-limiting abdominal involvement, characterized by hepatitis with mild elevation of am... | METHOTREXATE, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC-ND | 34322642 | 19,707,569 | 2021-03 |
What was the administration route of drug 'TOCILIZUMAB'? | Epstein-Barr Virus (EBV) acute acalculous cholecystitis in an immunocompromised adult patient: a case report and a literature review of a neglected clinical presentation.
Primary Epstein-Barr virus (EBV) infection may present with self-limiting abdominal involvement, characterized by hepatitis with mild elevation of am... | Subcutaneous | DrugAdministrationRoute | CC BY-NC-ND | 34322642 | 19,707,569 | 2021-03 |
What was the dosage of drug 'METHOTREXATE'? | Epstein-Barr Virus (EBV) acute acalculous cholecystitis in an immunocompromised adult patient: a case report and a literature review of a neglected clinical presentation.
Primary Epstein-Barr virus (EBV) infection may present with self-limiting abdominal involvement, characterized by hepatitis with mild elevation of am... | 10 mg (milligrams). | DrugDosage | CC BY-NC-ND | 34322642 | 19,707,569 | 2021-03 |
What was the dosage of drug 'TOCILIZUMAB'? | Epstein-Barr Virus (EBV) acute acalculous cholecystitis in an immunocompromised adult patient: a case report and a literature review of a neglected clinical presentation.
Primary Epstein-Barr virus (EBV) infection may present with self-limiting abdominal involvement, characterized by hepatitis with mild elevation of am... | 162 mg (milligrams). | DrugDosage | CC BY-NC-ND | 34322642 | 19,707,569 | 2021-03 |
What was the outcome of reaction 'Cholecystitis acute'? | Epstein-Barr Virus (EBV) acute acalculous cholecystitis in an immunocompromised adult patient: a case report and a literature review of a neglected clinical presentation.
Primary Epstein-Barr virus (EBV) infection may present with self-limiting abdominal involvement, characterized by hepatitis with mild elevation of am... | Recovered | ReactionOutcome | CC BY-NC-ND | 34322642 | 19,707,569 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Graft versus host disease in gastrointestinal tract'. | Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error of immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and ... | ALEMTUZUMAB, BUSULFAN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, ETANERCEPT, FILGRASTIM, FLUDARABINE PHOSPHATE, MYCOPHENOLATE MOFETIL, PENTOSTATIN, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34324127 | 20,028,213 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Graft versus host disease in liver'. | Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error of immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and ... | ALEMTUZUMAB, BUSULFAN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, ETANERCEPT, FILGRASTIM, FLUDARABINE PHOSPHATE, MYCOPHENOLATE MOFETIL, PENTOSTATIN, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34324127 | 20,028,213 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemosiderosis'. | Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error of immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and ... | ALEMTUZUMAB, BUSULFAN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, ETANERCEPT, FILGRASTIM, FLUDARABINE PHOSPHATE, MYCOPHENOLATE MOFETIL, PENTOSTATIN, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34324127 | 20,028,213 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune thrombocytopenia'. | Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error of immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and ... | BUSULFAN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, MYCOPHENOLATE MOFETIL | DrugsGivenReaction | CC BY | 34324127 | 20,020,115 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nodular regenerative hyperplasia'. | Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error of immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and ... | ALEMTUZUMAB, BUSULFAN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, ETANERCEPT, FILGRASTIM, FLUDARABINE PHOSPHATE, MYCOPHENOLATE MOFETIL, PENTOSTATIN, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34324127 | 20,028,213 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy non-responder'. | Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error of immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and ... | BUSULFAN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, FILGRASTIM, MYCOPHENOLATE MOFETIL, PENTOSTATIN, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34324127 | 20,036,086 | 2021-10 |
What was the dosage of drug 'BUSULFAN'? | Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error of immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and ... | LESS THAN 8 MG/KG | DrugDosageText | CC BY | 34324127 | 20,020,115 | 2021-10 |
What was the outcome of reaction 'Graft versus host disease in liver'? | Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error of immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and ... | Not recovered | ReactionOutcome | CC BY | 34324127 | 20,028,213 | 2021-10 |
What was the outcome of reaction 'Venoocclusive liver disease'? | Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.
Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error of immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and ... | Recovering | ReactionOutcome | CC BY | 34324127 | 20,027,089 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Liver injury'. | Liver injury caused by fenofibrate within 48 h after first administration: a case report.
BACKGROUND
Fenofibrate is commonly used in the treatment of dyslipidemia. Fenofibrate is related to mild aminotransferase elevations and in some cases severe chronic injury such as fibrosis or cirrhosis, resulting in liver transpl... | ALLOPURINOL, AROTINOLOL HYDROCHLORIDE, FELODIPINE, FENOFIBRATE, METFORMIN HYDROCHLORIDE, TELMISARTAN | DrugsGivenReaction | CC BY | 34325660 | 19,747,470 | 2021-07-29 |
What is the weight of the patient? | Liver injury caused by fenofibrate within 48 h after first administration: a case report.
BACKGROUND
Fenofibrate is commonly used in the treatment of dyslipidemia. Fenofibrate is related to mild aminotransferase elevations and in some cases severe chronic injury such as fibrosis or cirrhosis, resulting in liver transpl... | 95 kg. | Weight | CC BY | 34325660 | 19,747,470 | 2021-07-29 |
What was the administration route of drug 'FENOFIBRATE'? | Liver injury caused by fenofibrate within 48 h after first administration: a case report.
BACKGROUND
Fenofibrate is commonly used in the treatment of dyslipidemia. Fenofibrate is related to mild aminotransferase elevations and in some cases severe chronic injury such as fibrosis or cirrhosis, resulting in liver transpl... | Oral | DrugAdministrationRoute | CC BY | 34325660 | 19,747,470 | 2021-07-29 |
What was the outcome of reaction 'Liver injury'? | Liver injury caused by fenofibrate within 48 h after first administration: a case report.
BACKGROUND
Fenofibrate is commonly used in the treatment of dyslipidemia. Fenofibrate is related to mild aminotransferase elevations and in some cases severe chronic injury such as fibrosis or cirrhosis, resulting in liver transpl... | Recovered | ReactionOutcome | CC BY | 34325660 | 19,747,470 | 2021-07-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Melanosis coli in a peritoneal dialysis patient: a case report.
BACKGROUND
Patients who undergo peritoneal dialysis (PD) are at risk of gut bacteria translocation leading to peritonitis when there is chronic diarrhea. Chronic diarrhea is defined as any course of diarrhea that lasts at least 4 weeks, which can be contin... | BISACODYL, INSULIN NOS, LACTULOSE | DrugsGivenReaction | CC BY | 34325745 | 19,747,171 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal tract mucosal pigmentation'. | Melanosis coli in a peritoneal dialysis patient: a case report.
BACKGROUND
Patients who undergo peritoneal dialysis (PD) are at risk of gut bacteria translocation leading to peritonitis when there is chronic diarrhea. Chronic diarrhea is defined as any course of diarrhea that lasts at least 4 weeks, which can be contin... | BISACODYL, INSULIN NOS, LACTULOSE | DrugsGivenReaction | CC BY | 34325745 | 19,747,171 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypotension'. | Melanosis coli in a peritoneal dialysis patient: a case report.
BACKGROUND
Patients who undergo peritoneal dialysis (PD) are at risk of gut bacteria translocation leading to peritonitis when there is chronic diarrhea. Chronic diarrhea is defined as any course of diarrhea that lasts at least 4 weeks, which can be contin... | BISACODYL, INSULIN NOS, LACTULOSE | DrugsGivenReaction | CC BY | 34325745 | 19,747,171 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypovolaemic shock'. | Melanosis coli in a peritoneal dialysis patient: a case report.
BACKGROUND
Patients who undergo peritoneal dialysis (PD) are at risk of gut bacteria translocation leading to peritonitis when there is chronic diarrhea. Chronic diarrhea is defined as any course of diarrhea that lasts at least 4 weeks, which can be contin... | BISACODYL, INSULIN NOS, LACTULOSE | DrugsGivenReaction | CC BY | 34325745 | 19,747,171 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Weight decreased'. | Melanosis coli in a peritoneal dialysis patient: a case report.
BACKGROUND
Patients who undergo peritoneal dialysis (PD) are at risk of gut bacteria translocation leading to peritonitis when there is chronic diarrhea. Chronic diarrhea is defined as any course of diarrhea that lasts at least 4 weeks, which can be contin... | BISACODYL, INSULIN NOS, LACTULOSE | DrugsGivenReaction | CC BY | 34325745 | 19,747,171 | 2021-07-30 |
What was the dosage of drug 'BISACODYL'? | Melanosis coli in a peritoneal dialysis patient: a case report.
BACKGROUND
Patients who undergo peritoneal dialysis (PD) are at risk of gut bacteria translocation leading to peritonitis when there is chronic diarrhea. Chronic diarrhea is defined as any course of diarrhea that lasts at least 4 weeks, which can be contin... | AT NIGHT AFTER THE PROCEDURE | DrugDosageText | CC BY | 34325745 | 19,747,171 | 2021-07-30 |
What was the dosage of drug 'LACTULOSE'? | Melanosis coli in a peritoneal dialysis patient: a case report.
BACKGROUND
Patients who undergo peritoneal dialysis (PD) are at risk of gut bacteria translocation leading to peritonitis when there is chronic diarrhea. Chronic diarrhea is defined as any course of diarrhea that lasts at least 4 weeks, which can be contin... | 45 ML DAILY; THREE TIME A DAY | DrugDosageText | CC BY | 34325745 | 19,747,171 | 2021-07-30 |
What was the outcome of reaction 'Diarrhoea'? | Melanosis coli in a peritoneal dialysis patient: a case report.
BACKGROUND
Patients who undergo peritoneal dialysis (PD) are at risk of gut bacteria translocation leading to peritonitis when there is chronic diarrhea. Chronic diarrhea is defined as any course of diarrhea that lasts at least 4 weeks, which can be contin... | Recovered | ReactionOutcome | CC BY | 34325745 | 19,747,171 | 2021-07-30 |
What was the outcome of reaction 'Gastrointestinal tract mucosal pigmentation'? | Melanosis coli in a peritoneal dialysis patient: a case report.
BACKGROUND
Patients who undergo peritoneal dialysis (PD) are at risk of gut bacteria translocation leading to peritonitis when there is chronic diarrhea. Chronic diarrhea is defined as any course of diarrhea that lasts at least 4 weeks, which can be contin... | Recovering | ReactionOutcome | CC BY | 34325745 | 19,747,171 | 2021-07-30 |
What was the outcome of reaction 'Hypovolaemic shock'? | Melanosis coli in a peritoneal dialysis patient: a case report.
BACKGROUND
Patients who undergo peritoneal dialysis (PD) are at risk of gut bacteria translocation leading to peritonitis when there is chronic diarrhea. Chronic diarrhea is defined as any course of diarrhea that lasts at least 4 weeks, which can be contin... | Recovering | ReactionOutcome | CC BY | 34325745 | 19,747,171 | 2021-07-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dermatitis atopic'. | Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis.
In the therapeutic arsenal to treat moderate to severe psoriasis, the new agents are secukinumab and ustekinumab, which are fully human monoclonal antibodies, directed against IL-17A and IL-12/23, respectively, which have been show... | SECUKINUMAB | DrugsGivenReaction | CC BY-NC | 34326727 | 16,727,046 | 2021 |
What is the weight of the patient? | Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis.
In the therapeutic arsenal to treat moderate to severe psoriasis, the new agents are secukinumab and ustekinumab, which are fully human monoclonal antibodies, directed against IL-17A and IL-12/23, respectively, which have been show... | 60 kg. | Weight | CC BY-NC | 34326727 | 16,727,046 | 2021 |
What was the administration route of drug 'SECUKINUMAB'? | Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis.
In the therapeutic arsenal to treat moderate to severe psoriasis, the new agents are secukinumab and ustekinumab, which are fully human monoclonal antibodies, directed against IL-17A and IL-12/23, respectively, which have been show... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34326727 | 16,727,046 | 2021 |
What was the outcome of reaction 'Dermatitis atopic'? | Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis.
In the therapeutic arsenal to treat moderate to severe psoriasis, the new agents are secukinumab and ustekinumab, which are fully human monoclonal antibodies, directed against IL-17A and IL-12/23, respectively, which have been show... | Recovering | ReactionOutcome | CC BY-NC | 34326727 | 16,727,046 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated encephalitis'. | Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma.
While immunotherapy with nivolumab is promising for patients with renal cell carcinoma (RCC), overactivation of the immune system can lead to serious side effects. Immune-related meningoencephalitis without a viral or microbial e... | NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 34326741 | 19,647,255 | 2021 |
What is the weight of the patient? | Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma.
While immunotherapy with nivolumab is promising for patients with renal cell carcinoma (RCC), overactivation of the immune system can lead to serious side effects. Immune-related meningoencephalitis without a viral or microbial e... | 117.01 kg. | Weight | CC BY-NC | 34326741 | 19,647,255 | 2021 |
What was the dosage of drug 'NIVOLUMAB'? | Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma.
While immunotherapy with nivolumab is promising for patients with renal cell carcinoma (RCC), overactivation of the immune system can lead to serious side effects. Immune-related meningoencephalitis without a viral or microbial e... | 7 CYCLES | DrugDosageText | CC BY-NC | 34326741 | 19,647,255 | 2021 |
What was the outcome of reaction 'Immune-mediated encephalitis'? | Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma.
While immunotherapy with nivolumab is promising for patients with renal cell carcinoma (RCC), overactivation of the immune system can lead to serious side effects. Immune-related meningoencephalitis without a viral or microbial e... | Recovered | ReactionOutcome | CC BY-NC | 34326741 | 19,647,255 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to central nervous system'. | Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation.
Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancer... | ERLOTINIB | DrugsGivenReaction | CC BY-NC | 34326746 | 20,854,117 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oedema'. | Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation.
Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancer... | ERLOTINIB | DrugsGivenReaction | CC BY-NC | 34326746 | 20,854,117 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Seizure'. | Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation.
Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancer... | ERLOTINIB | DrugsGivenReaction | CC BY-NC | 34326746 | 20,854,117 | 2021 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.